12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lixivaptan regulatory update

Cornerstone said FDA issued a complete response letter for an NDA for lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure (CHF) and euvolemic hyponatremia associated with syndrome of...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >